Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects.

@article{Hartman2013IncretinbasedTF,
  title={Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects.},
  author={Israel Hartman and Edward Rojas and Daloha Rodr{\'i}guez-Molina},
  journal={American journal of therapeutics},
  year={2013},
  volume={20 4},
  pages={384-93}
}
The prevalence of type 2 diabetes mellitus has increased at an alarming rate in recent years. Recent estimations project that 366 million people could have diabetes by 2030. The incretin system emerges as a new target for type 2 diabetes therapy, and new molecules are being approved for its use in humans since the year 2005. These agents could be divided into 2 main groups, glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 inhibitors. Endogenous GLP-1 is an incretin… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS